Genovese MC, Fleischmann R, Combe B, et al. Upadacitinib (ABT-494) in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological Dmards: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of a Selective JAK-1 Inhibitor. ACR 2017, abstract 10L.
Nieuwe EULAR- en GRAPPA-richtlijnen voor PsA: zoek de verschillen
feb 2017 | Arthritis psoriatica